OliX Pharmaceuticals, Inc.

---

OliX Pharmaceuticals, Inc.

OliX Pharmaceuticals Inc. is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes, based on its own proprietary RNAi technology. It secures the technology of cell-penetrating asymmetric small interfering RNA (cp-asiRNA) which can be delivered to target cells/tissues without the aid of any delivery vehicle, along with reduced non-specific effects over conventional siRNA. The company is currently developing novel therapeutic programs for treatment of various diseases with high unmet medical needs, including hypertrophic scar, dry form of age-related macular degeneration (AMD), subretinal fibrosis, and idiopathic pulmonary fibrosis (IPF).

Summary Information

- Industry: Biotechnology

- Business area: RNAi therapeutics

- Foundation: February 2010

- Location: Suwon, South Korea

- Website: www.olixpharma.com

- CEO: Dr. Dong ki Lee

Pipeline

1) OLX101 (hypertrophic scar)

With OliX’s proprietary RNAi platform technology, OLX101 program is currently in clinical trial in Korea and UK, for the treatment of hypertrophic scar.

2) OLX201 (idiopathic pulmonary fibrosis, IPF)

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and most deadly type of interstitial lung diseases.

3) OLX301 (age-related macular degeneration, AMD)

There are no approved therapies for dry age-related macular degeneration (AMD) and subretinal fibrosis. Working with Prof. Jayakrishna Ambati in University of Virginia, OLX301A and OLX301D programs are under preclinical studies to treat these conditions with high unmet medical needs.

References

Hwang J, Chang C, Kim JH, Oh CT, Lee HN, et al. Development of Cell-Penetrating Asymmetric Interfering RNA Targeting Connective Tissue Growth Factor. J Inv Dermatol 2016;136:2305-2313

OliX Pharmaceuticals receives Clinical Trial Authorization in the UK to initiate Phase I study with OLX10010, an anti-scar RNAi therapeutics. PR Newswire. May 29, 2018

A phase 1, randomized, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetic profiles of OLX10010 in healthy subjects compared to placebo. ISRCTN64317949

A Study to Evaluate Safety and PK Profiles of OLX10010 in Healthy Subjects. NCT03569267 (ClinicalTrials.gov)

Web site

Web site http://www.olixpharma.com

Youtube Channel https://www.youtube.com/channel/UCEcE8Rqw1aU2XcmG5EPMX6g

This article "OliX Pharmaceuticals, Inc." is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:OliX Pharmaceuticals, Inc.. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.

---